Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients

Windy Berkofsky-Fessler, Tri Q. Nguyen, Paul Delmar, Juliette Molnos, Charu Kanwal, Wanda DePinto, James Rosinski, Patricia McLoughlin, Steve Ritland, Mark DeMario, Krishna Tobon, John F. Reidhaar-Olson, Ruediger Rueger, Holly Hilton

Research output: Contribution to journalArticle

16 Scopus citations


A genomics-based approach to identify pharmacodynamic biomarkers was used for a cyclin-dependent kinase inhibitory drug. R547 is a potent cyclin-dependent kinase inhibitor with a potent antiproliferative effect at pharmacologically relevant doses and is currently in phase I clinical trials. Using preclinical data derived from microarray experiments,we identified pharmacodynamic biomarkers to test in blood samples from patients in clinical trials. These candidate biomarkers were chosen based on several criteria: relevance to the mechanism of action of R547, dose responsiveness in preclinical models, and measurable expression in blood samples. We identified 26 potential biomarkers of R547 action and tested their clinical validity in patient blood samples by quantitative real-time PCR analysis. Based on the results, eight genes (FLJ44342, CD86, EGR1, MKI67, CCNB1, JUN, HEXIM1, and PFAAP5) were selected as dose-responsive pharmacodynamic biomarkers for phase II clinical trials.

Original languageEnglish (US)
Pages (from-to)2517-2525
Number of pages9
JournalMolecular cancer therapeutics
Issue number9
Publication statusPublished - Sep 1 2009


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this